drugset / Trial / NCT03542175
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Phase 1
Completed
31 enrolled
Memorial Sloan Kettering Cancer Center
Clovis Oncology, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast cancer.
Timeline
- Start
- 2018-05-23
- Primary completion
- 2024-07-25
- Completion
- 2025-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rucaparib | Small molecule | 200 mg | — |
| Subject | Rucaparib | Small molecule | 300 mg | — |
| Subject | Rucaparib | Small molecule | 400 mg | — |